You reached your goal weight, and now the question isn't *how do I lose more* — it's *how do I keep this without losing the metabolism and muscle I still have*. That shift, from a loss phase to a hold phase, changes almost everything about how a thoughtful provider watches your numbers.
Why a maintenance phase is its own problem, not a smaller version of loss
The biology of weight regain is well documented. After significant weight loss, the body defends its prior mass through durable changes: lower circulating leptin, higher ghrelin, and reduced energy expenditure that can persist long after the loss itself [1]. In one influential study following participants a year after a supervised loss program, several appetite- and energy-regulating hormones remained shifted in a direction that favors regain [1]. This is not a willpower story — it is a physiology story.
That is precisely why the research on stopping GLP-1 therapy matters. In the STEP 1 trial extension, participants who withdrew from semaglutide and lifestyle support regained a substantial share of lost weight over the following year, and much of the improvement in cardiometabolic markers moved back toward baseline [2]. The practical read for an optimizer: the medication was doing ongoing work, and removing it abruptly removed that work.
This is the framework for thinking about maintenance as a distinct goal. The question a provider engages with is not "how do we keep pushing weight down" but "what is the lowest level of pharmacologic and lifestyle support that holds a defended set point steady, while protecting lean mass and metabolic function."
What "microdosing" actually means in coordinated care
The word gets used loosely online. In a clinical context, it is not a magic small number and it is not a fixed protocol you can copy from a forum. It refers to a provider-directed approach where the objective has changed — from titrating upward toward a therapeutic loss dose, to identifying a lower maintenance level that keeps you stable.
A few honest points an intellectually engaged reader should hold:
- There is no established, universally validated "maintenance microdose." GLP-1 receptor agonists were studied and labeled around specific dosing schedules for chronic weight management [3]. A lower-intensity maintenance strategy is an individualized clinical decision, not a manufacturer-defined regimen.
- Any dose — up, down, or held — is decided by an independent licensed provider based on your history, current labs, and response. A prescription is never guaranteed.
- This article does not and cannot give you dosing instructions. That is the provider's role, and it belongs in your visit.
What you *can* bring to that visit is a systems mindset: clear goals, a record of how you responded during your loss phase, and a willingness to track the right signals over time.
Source: [1] Long-Term Persistence of Hormonal Adaptations to Weight Loss (Sumithran et al., NEJM), [2] Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension
The signals a provider watches when the goal is "hold"
Body composition, not just the scale
Rapid or aggressive weight loss can carry a meaningful proportion of lean mass alongside fat mass [4]. In a maintenance phase, the scale becomes a crude instrument. A provider partnering on maintenance is often more interested in *what* the body is made of than the single number. Tools like DEXA can estimate fat mass, lean mass, and bone density, giving a more honest picture of whether you are holding your result or quietly losing muscle [4]. Grip strength and functional benchmarks add context that no scale provides.
Protein intake and resistance training as the muscle-protecting base
No medication substitutes for the two inputs most associated with preserving lean mass during and after weight change: adequate dietary protein and progressive resistance training. Major nutrition and sports-medicine guidance consistently points to higher protein needs during energy restriction and to resistance exercise as the primary stimulus for muscle retention [5]. A provider watching a maintenance phase will typically want to know these are in place before adjusting anything pharmacologic.
Metabolic and safety labs
Because GLP-1 therapy touches glucose regulation, a maintenance plan is usually reviewed alongside markers such as fasting glucose and HbA1c, a lipid panel, and — depending on your history — kidney and liver function [3]. The point is not to chase a perfect number but to confirm the metabolic gains you earned are holding, and to catch drift early. Provider labeling for these molecules also flags specific safety considerations, including gastrointestinal effects and gallbladder-related risks, which is another reason ongoing review beats a set-and-forget refill [3].
Appetite, energy, and the honest subjective read
The hormonal defense of body weight shows up as returning hunger and food preoccupation [1]. A provider engaged in maintenance treats these subjective signals as data, not as failure — they help distinguish "the plan is holding" from "the plan is drifting."
Source: [3] FDA Prescribing Information: Wegovy (semaglutide) injection, [4] Dual-energy X-ray absorptiometry for body composition assessment (NIH/PMC review)
A reasonable cadence for a maintenance partnership
Maintenance is a review relationship, not a one-time script. A practical rhythm often looks like a baseline assessment when transitioning out of the loss phase, periodic lab and body-composition check-ins, and provider-directed adjustments only when the data and your experience warrant them. The exact schedule is individualized.
A note on compounded options
Some maintenance conversations involve compounded formulations. It is important to understand what that means. Compounded medications are not reviewed or approved by the FDA for safety, effectiveness, or quality. Compounded products are not equivalent to or interchangeable with any FDA-approved brand-name drug. Availability varies by state. Whether a compounded or an FDA-approved product is appropriate — or whether medication belongs in your plan at all — is a clinical decision for an independent licensed provider.
The mindset shift, in one sentence
A loss phase asks "how far can we go"; a maintenance phase asks "how little support holds this steady while protecting muscle and metabolism" — and it answers that question with labs, body composition, and an ongoing provider relationship, not a fixed ladder.
*This article is educational and is not medical advice, diagnosis, or a recommendation to take any specific medication. Talk with a licensed provider about your individual situation.*
Where Velri fits
Velri is a technology and coordination company — it does not provide medical care. For readers thinking about a maintenance phase, Velri can help coordinate the pieces: arranging lab work, connecting you with an independent, licensed provider group for an evaluation of whether a maintenance approach is appropriate for you, and — if that provider writes a prescription — coordinating with an independent licensed pharmacy for fulfillment. Care decisions, including any prescription and any dose, are made solely by the independent provider. Nothing here guarantees treatment.
